RE:RE:RE:RE:Where we are now as ONCY shareholdersWrong on thinking about the use of pelareorep as a "salvage" therapy since in pancreatic cancer for example thete is no real effective therapy, however pelareorep + immune checkpoint inhibitor was able to be an effective therapy, leading to a "cure" in 1 patient and partial responses in most of the rest studied.
Then there is the use of pelareorep + immune checkpoint inhibitors in the treatment of early breadt cancer.
However why you may think of pelareorep as a salvage therapy is because the FDA requires that an emerging new cancer therapy demonstrates safety and that usually happens in late stage patients. Now that has been accomplished there is little for ONCY's acquirer to stop using pelareorep in earlier disease patients.